Sentinel Lymph Node Working Group Publications

  1.  Factors predicting survival in thick melanoma: Do all thick melanomas have the same prognosis?

    Han D, Han G, Morrison S, Leong SP, Kashani-Sabet M, Vetto J, White R, Schneebaum S, Pockaj B, Mozzillo N, Sondak VK, Zager JS.Surgery. 2020 Sep;168(3):518-526. doi: 10.1016/j.surg.2020.04.048. Epub 2020 Jul 12.PMID: 32669204

  2. Sentinel Lymph Node Biopsy Is Prognostic in Thickest Melanoma Cases and Should Be Performed for Thick Melanomas.

    Han D, Han G, Duque MT, Morrison S, Leong SP, Kashani-Sabet M, Vetto J, White R, Schneebaum S, Pockaj B, Mozzillo N, Sondak VK, Zager JS.Ann Surg Oncol. 2020 Jun 10. doi: 10.1245/s10434-020-08706-0. Online ahead of print.PMID: 32524460

  3. Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival.

    Thomas DC, Han G, Leong SP, Kashani-Sabet M, Vetto J, Pockaj B, White RL, Faries MB, Schneebaum S, Mozzillo N, Charney KJ, Sondak VK, Messina JL, Zager JS, Han D.Ann Surg Oncol. 2019 Jul;26(7):2254-2262. doi: 10.1245/s10434-019-07369-w. Epub 2019 Apr 22.PMID: 31011906

  4. Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit.

    Klemen ND, Han G, Leong SP, Kashani-Sabet M, Vetto J, White R, Schneebaum S, Pockaj B, Mozzillo N, Charney K, Hoekstra H, Sondak VK, Messina JL, Zager JS, Han D.J Surg Oncol. 2019 Jun;119(8):1053-1059. doi: 10.1002/jso.25444. Epub 2019 Mar 18.PMID: 30883771

  5. Microsatellitosis in Patients with Melanoma.

    Karakousis GC, Gimotty PA, Leong SP, Pockaj BA, White RL, O'Donoghue C, Sinnamon AJ, Bartlett EK, Dueck AC, Gould Rothberg BE, Messina JL, Vetto JT, Sondak VK, Schneebaum S, Kashani-Sabet M, Han D, Faries MB, Zager JS; with the Sentinel Lymph Node Working Group.Ann Surg Oncol. 2019 Jan;26(1):33-41. doi: 10.1245/s10434-018-7006-4. Epub 2018 Nov 12.PMID: 30421045

  6. Stratifying SLN incidence in intermediate thickness melanoma patients.

    Chang JM, Kosiorek HE, Dueck AC, Leong SPL, Vetto JT, White RL, Avisar E, Sondak VK, Messina JL, Zager JS, Garberoglio C, Kashani-Sabet M, Pockaj BA.Am J Surg. 2018 Apr;215(4):699-706. doi: 10.1016/j.amjsurg.2017.12.009. Epub 2017 Dec 14.PMID: 29502857 

  7. Is pelvic sentinel node biopsy necessary for lower extremity and trunk melanomas?

    Schuitevoerder D, Leong SPL, Zager JS, White RL, Avisar E, Kosiorek H, Dueck A, Fortino J, Kashani-Sabet M, Hart K, Vetto JT.Am J Surg. 2017 May;213(5):921-925. doi: 10.1016/j.amjsurg.2017.03.028. Epub 2017 Mar 27.PMID: 28411863

  8. Clinical utilities and biological characteristics of melanoma sentinel lymph nodes.

    Han D, Thomas DC, Zager JS, Pockaj B, White RL, Leong SP.World J Clin Oncol. 2016 Apr 10;7(2):174-88. doi: 10.5306/wjco.v7.i2.174.PMID: 27081640 

  9. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients.

    Balch CM, Thompson JF, Gershenwald JE, Soong SJ, Ding S, McMasters KM, Coit DG, Eggermont AM, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, Ross MI, Byrd DR, Cochran AJ, Mihm MC Jr, Morton DL, Atkins MB, Flaherty KT, Sondak VK.Ann Surg Oncol. 2014 Apr;21(4):1075-81. doi: 10.1245/s10434-013-3464-x. Epub 2014 Feb 15.PMID: 24531700 

  10. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.

    Han D, Zager JS, Shyr Y, Chen H, Berry LD, Iyengar S, Djulbegovic M, Weber JL, Marzban SS, Sondak VK, Messina JL, Vetto JT, White RL, Pockaj B, Mozzillo N, Charney KJ, Avisar E, Krouse R, Kashani-Sabet M, Leong SP.J Clin Oncol. 2013 Dec 10;31(35):4387-93. doi: 10.1200/JCO.2013.50.1114. Epub 2013 Nov 4.PMID: 24190111

  11. Age as a prognostic factor in patients with localized melanoma and regional metastases.

    Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Coit DG, Atkins MB, Ding S, Cochran AJ, Eggermont AM, Flaherty KT, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sondak VK.Ann Surg Oncol. 2013 Nov;20(12):3961-8. doi: 10.1245/s10434-013-3100-9. Epub 2013 Jul 10.PMID: 23838920 

  12. Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma.

    Sondak VK, King DW, Zager JS, Schneebaum S, Kim J, Leong SP, Faries MB, Averbook BJ, Martinez SR, Puleo CA, Messina JL, Christman L, Wallace AM.Ann Surg Oncol. 2013 Feb;20(2):680-8. doi: 10.1245/s10434-012-2612-z. Epub 2012 Oct 3.PMID: 23054107 

  13. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database.

    White RL Jr, Ayers GD, Stell VH, Ding S, Gershenwald JE, Salo JC, Pockaj BA, Essner R, Faries M, Charney KJ, Avisar E, Hauschild A, Egberts F, Averbook BJ, Garberoglio CA, Vetto JT, Ross MI, Chu D, Trisal V, Hoekstra H, Whitman E, Wanebo HJ, Debonis D, Vezeridis M, Chevinsky A, Kashani-Sabet M, Shyr Y, Berry L, Zhao Z, Soong SJ, Leong SP; Sentinel Lymph Node Working Group.Ann Surg Oncol. 2011 Dec;18(13):3593-600. doi: 10.1245/s10434-011-1826-9. Epub 2011 Jun 7.PMID: 21647761 

  14. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.

    Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC Jr, Morton DL, Sondak VK.J Clin Oncol. 2011 Jun 1;29(16):2199-205. doi: 10.1200/JCO.2010.31.5812. Epub 2011 Apr 25.PMID: 21519009 

  15. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.

    Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sondak VK.J Clin Oncol. 2010 May 10;28(14):2452-9. doi: 10.1200/JCO.2009.27.1627. Epub 2010 Apr 5.PMID: 20368546 

  16. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients.

    Leong SP, Accortt NA, Essner R, Ross M, Gershenwald JE, Pockaj B, Hoekstra HJ, Garberoglio C, White RL Jr, Chu D, Biel M, Charney K, Wanebo H, Avisar E, Vetto J, Soong SJ; Sentinel Lymph N4ode Working Group.Arch Otolaryngol Head Neck Surg. 2006 Apr;132(4):370-3. doi: 10.1001/archotol.132.4.370.PMID: 16618904

  17. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study.

    Wong SL, Morton DL, Thompson JF, Gershenwald JE, Leong SP, Reintgen DS, Gutman H, Sabel MS, Carlson GW, McMasters KM, Tyler DS, Goydos JS, Eggermont AM, Nieweg OE, Cosimi AB, Riker AI, G Coit D.Ann Surg Oncol. 2006 Jun;13(6):809-16. doi: 10.1245/ASO.2006.03.058. Epub 2006 Apr 12.PMID: 16604476